Dr. Halabi Discusses Overall Survival Between African-American and Caucasian Men With mCRPC

Video

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses overall survival between African-American and Caucasian men with metastatic castration-resistant prostate cancer.

Susan Halabi, PhD, professor of biostatistics and bioinformatics, School of Medicine, Duke Cancer Institute, discusses overall survival (OS) between African-American and Caucasian men with metastatic castration-resistant prostate cancer (mCRPC).

Based on population-level data, researchers wanted to test a hypothesis on the OS outcomes in African-American and Caucasian men. The initial hypothesis was that African-American men would have worse OS outcomes than Caucasian men. In order to test the hypothesis, researchers pulled data from 9 randomized phase III trials, comprised of over 8000 men. Eighty-five percent were Caucasian, and only 6% were African-American, says Halabi.

In the initial analysis, there were no differences in OS between African-American and Caucasian men. The median OS was 21 months. An analysis adjusted for important prognostic factors like age, prostate-specific antigen level, and alkaline phosphatase showed a hazard ratio of 0.81, favoring African-American men. Therefore, the risk of death was about 19% lower for African-American men than Caucasian men, states Halabi.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD